BONN, Germany (AP) — Yannic Seidenberg, who won the silver medal with the German men's hockey team at the 2018 Olympics, has had his doping ban cut by 18 months.
The 40-year-old forward had filed an appeal against a four-year ban imposed last year over the alleged use of testosterone and another banned substance, DHEA.
Germany's anti-doping agency said Wednesday it and the World Anti-Doping Agency reached a “case resolution agreement” with Seidenberg that suspends 12 months of the ban and cuts another six months off for delays that were deemed not to be the player's fault.
The ban had been previously backdated to start from 2022 and will now expire in March 2025.
It did not affect the Olympic silver medal Seidenberg won in 2018.
Seidenberg is the younger brother of Dennis Seidenberg, who was a defenseman on the Boston Bruins team that won the Stanley Cup in 2011.
AP sports: https://apnews.com/sports
FILE - Germany's Yannic Seidenberg, left, challenges for the puck with Finland's Kasperi Kapanen, right, during their Ice Hockey World Championships group B match at the Jyske Bank Boxen arena in Herning, Denmark, Sunday, May 13, 2018. (AP Photo/Petr David Josek, file)
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Jan 12, 2026--
ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To support its growth in the region, ChemWerth has hired Chandrakanth Reddy as general sales manager of its India office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260111302280/en/
“The addition of a general sales manager in India signals our desire to grow our presence and customer base in the world’s most important generic pharmaceutical market,” said Pete Werth III, president, ChemWerth. “Chandrakanth will add tremendous value for our customers and contract manufacturing organizations (CMOs) in India.”
Reddy is a seasoned pharmaceutical professional with more than 16 years of experience spanning API sourcing, business development, market expansion and regulatory-driven commercial strategy. He has successfully led high-value markets across India, the Middle East, North Africa, Europe, and the United States, building strong customer partnerships and supporting sustainable revenue growth.
In his new role, Reddy will be responsible for leading ChemWerth’s sales strategy in India and strengthening regional customer relationships. He will also support the company’s focused initiative to roll out new generic APIs in the market, including fermentation, peptide and oncology injectable APIs.
“After reviewing ChemWerth’s strategic plan to unveil a strong pipeline of new generic fermentation, peptide and oncology injectable APIs for the Indian market, I knew that was something I wanted to be a part of,” said Reddy.
About ChemWerth, Inc.:
Established in 1982, ChemWerth is a full-service generic active pharmaceutical ingredient (API) development and supply company providing cGMP-quality APIs to regulated markets worldwide. ChemWerth is a global company headquartered in the United States, with offices in China and India. For more information, please visit www.chemwerth.com.
Chandrakanth Reddy has joined ChemWerth, Inc., as general sales manager of its India office.
